ESC 2008 急性肺动脉栓塞指南

ESC GUIDELINES Guidelines on the diagnosis and management of acute pulmonary embolism The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Authors/Task Force Members: Adam Torbicki, Chairperson (Poland)*, Arnaud Perrier (Switzerland), Stavros Konstantinides (Germany), Giancarlo Agnelli (Italy), Nazzareno Galie` (Italy), Piotr Pruszczyk (Poland), Frank Bengel (USA), Adrian J.B. Brady (UK), Daniel Ferreira (Portugal), Uwe Janssens (Germany), Walter Klepetko (Austria), Eckhard Mayer (Germany), Martine Remy-Jardin (France), and Jean-Pierre Bassand (France) Full author affiliations can be found on the page dedicated to these guidelines on the ESC Web Site (www.escardio.org/guidelines) ESC Committee for Practice Guidelines (CPG): Alec Vahanian, Chairperson (France), John Camm (UK), Raffaele De Caterina (Italy), Veronica Dean (France), Kenneth Dickstein (Norway), Gerasimos Filippatos (Greece), Christian Funck-Brentano (France), Irene Hellemans (Netherlands), Steen Dalby Kristensen (Denmark), Keith McGregor (France), Udo Sechtem (Germany), Sigmund Silber (Germany), Michal Tendera (Poland), Petr Widimsky (Czech Republic), and Jose Luis Zamorano (Spain) Document Reviewers: Jose-Luis Zamorano, (CPG Review Coordinator) (Spain), Felicita Andreotti (Italy), Michael Ascherman (Czech Republic), George Athanassopoulos (Greece), Johan De Sutter (Belgium), David Fitzmaurice (UK), Tamas Forster (Hungary), Magda Heras (Spain), Guillaume Jondeau (France), Keld Kjeldsen (Denmark), Juhani Knuuti (Finland), Irene Lang (Austria), Mattie Lenzen (The Netherlands), Jose Lopez-Sendon (Spain), Petros Nihoyannopoulos (UK), Leopoldo Perez Isla (Spain), Udo Schwehr (Germany), Lucia Torraca (Italy), and Jean-Luc Vachiery (Belgium) Keywords Pulmonary embolism † Venous thrombosis † Shock † Hypotension † Chest pain † Dyspnoea † Heart failure † Diagnosis † Prognosis † Treatment † Guidelines * Corresponding author. Department of Chest Medicine, Institute for Tuberculosis and Lung Diseases, ul. Plocka 26, 01–138 Warsaw, Poland. Tel: þ48 22 431 2114, Fax: þ48 22 431 2414; Email: a.torbicki@igichp.edu.pl The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to Oxford University Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC. Disclaimer. The ESC Guidelines represent the views of the ESC and were arrived at after careful consideration of the available evidence at the time they were written. Health professionals are encouraged to take them fully into account when exercising their clinical judgement. The guidelines do not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patients, in consultation with that patient, and where appropriate and necessary the patient’s guardian or carer. It is also the health professional’s responsibility to verify the rules and regulations applicable to drugs and devices at the time of prescription. & The European Society of Cardiology 2008. All rights reserved. For permissions please email: journals.permissions@oxfordjournals.org European Heart Journal (2008) 29, 2276–2315 doi:10.1093/eurheartj/ehn310 Table of contents List of acronyms and abbreviations . . . . . . . . . . . . . . . . . . 2277 Preamble . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2277 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2278 Epidemiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2279 Predisposing factors . . . . . . . . . . . . . . . . . . . . . . . . . 2279 Natural history . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2279 Pathophysiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2280 Severity of pulmonary embolism . . . . . . . . . . . . . . . . . 2281 Diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2282 Clinical presentation . . . . . . . . . . . . . . . . . . . . . . . . . 2282 Assessment of clinical probability . . . . . . . . . . . . . . . . 2282 D-dimer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2283 Compression ultrasonography and computed tomographic venography . . . . . . . . . . . . . . . . . . . . . . 2284 Ventilation–perfusion scintigraphy . . . . . . . . . . . . . . . . 2284 Computed tomography . . . . . . . . . . . . . . . . . . . . . . . 2285 Pulmonary angiography . . . . . . . . . . . . . . . . . . . . . . . 2286 Echocardiography . . . . . . . . . . . . . . . . . . . . . . . . . . . 2287 Diagnostic strategies . . . . . . . . . . . . . . . . . . . . . . . . . 2288 Suspected high-risk pulmonary embolism . . . . . . . . . 2288 Suspected non-high-risk pulmonary embolism . . . . . . 2289 Prognostic assessment . . . . . . . . . . . . . . . . . . . . . . . . . . . 2292 Clinical assessment of haemodynamic status . . . . . . . . . 2292 Markers of right ventricular dysfunction . . . . . . . . . . . . 2292 Markers of myocardial injury . . . . . . . . . . . . . . . . . . . 2293 Additional risk markers . . . . . . . . . . . . . . . . . . . . . . . 2294 Strategy of prognostic assessment . . . . . . . . . . . . . . . . 2294 Treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2295 Haemodynamic and respiratory support . . . . . . . . . . . . 2295 Thrombolysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2296 Surgical pulmonary embolectomy . . . . . . . . . . . . . . . . 2297 Percutaneous catheter embolectomy and fragmentation . 2297 Initial anticoagulation . . . . . . . . . . . . . . . . . . . . . . . . . 2298 Therapeutic strategies . . . . . . . . . . . . . . . . . . . . . . . . 2299 High-risk pulmonary embolism . . . . . . . . . . . . . . . . 2299 Non-high-risk pulmonary embolism . . . . . . . . . . . . . 2300 Long-term anticoagulation and secondary prophylaxis . . . 2301 Venous filters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2302 Specific problems . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2303 Pregnancy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2303 Malignancy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2304 Right heart thrombi . . . . . . . . . . . . . . . . . . . . . . . . . 2304 Heparin-induced thrombocytopenia . . . . . . . . . . . . . . . 2305 Chronic thromboembolic pulmonary hypertension . . . . . 2305 Non-thrombotic pulmonary embolism . . . . . . . . . . . . . 2306 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2307 List of acronyms and abbreviations aPTT activated partial thromboplastin time anti-Xa anti-factor Xa activity BNP brain natriuretic peptide CI confidence interval CT computed tomography CTEPH chronic thromboembolic pulmonary hypertension CUS compression venous ultrasonography DVT deep vein thrombosis ECG electrocardiogram ELISA enzyme-linked immunoabsorbent assay HIT heparin-induced thrombocytopenia ICOPER International Cooperative Pulmonary Embolism Registry INR international normalized ratio IVC inferior vena cava LMWH low molecular weight heparin LV left ventricle MDCT multidetector computed tomography NPV negative predictive value NT-proBNP N-terminal proBNP OR odds ratio PaO2 arterial oxygen pressure PE pulmonary embolism PIOPED Prospective Investigation On Pulmonary Embolism Diagnosis study PPV positive predictive value rtPA recombinant tissue plasminogen activator RV right ventricle RVD right ventricular dysfunction SBP systolic blood pressure SDCT single-detector computed tomography VKA vitamin K antagonist VTE venous thromboembolism V/Q scan ventilation–perfusion scintigraphy Preamble Guidelines and Expert Consensus Documents summarize and evaluate all currently available evidence on a particular issue with the aim of assisting physicians in selecting the best management strategies for a typical patient, suffering from a given condition, taking into account the impact on outcome, as well as the risk/ benefit ratio of particular diagnostic or therapeutic means. Guide- lines are no substitutes for textbooks. The legal implications of medical guidelines have been discussed previously. A great number of Guidelines and Expert Consensus Docu- ments have been issued in recent years by the European Society of Cardiology (ESC) as well as by other societies and organizations. Because of the impact on clinical practice, quality criteria for the development of guidelines have been established in order to make all decisions transparent to the user. The recommendations for formulating and issuing ESC Guidelines and Expert Consensus Documents can be found on the ESC Web Site (http:\\www. escardio.org/guidelines). In brief, experts in the field are selected and undertake a com- prehensive review of the published evidence for management and/or prevention of a given condition. A critical evaluation of diagnostic and therapeutic procedures is performed, including assessment of the risk–benefit ratio. Estimates of expected health outcomes for larger societies are included, where ESC Guidelines 2277 data exist. The level of evidence and the strength of recommen- dation of particular treatment options are weighed and graded according to predefined scales, as outlined in Tables 1 and 2. The experts of the writing panels have provided disclosure statements of all relationships they may have which might be per- ceived as real or potential sources of conflicts of interest. These disclosure forms are kept on file at the European Heart House, headquarters of the ESC. Any changes in conflict of interest that arise during the writing period must be notified to the ESC. The Task Force report was entirely supported financially by the European Society of Cardiology and was developed without any involvement of the industry. The ESC Committee for Practice Guidelines (CPG) supervises and coordinates the preparation of new Guidelines and Expert Consensus Documents produced by Task Forces, expert groups or consensus panels. The Committee is also responsible for the endorsement process of these Guidelines and Expert Consensus Documents or statements. Once the document has been finalized and approved by all the experts involved in the Task Force, it is submitted to outside specialists for review. The document is revised, and finally approved by the CPG and subsequently published. After publication, dissemination of the message is of paramount importance. Pocket-sized versions and personal digital assistant (PDA)-downloadable versions are useful at the point of care. Some surveys have shown that the intended end-users are some- times not aware of the existence of guidelines, or simply do not translate them into practice; this is why implementation programmes for new guidelines form an important component of the dissemination of knowledge. Meetings are organized by the ESC and are directed towards its member national societies and key opinion leaders in Europe. Implementation meetings can also be undertaken at national level, once the guidelines have been endorsed by the ESC member societies and translated into the national language. Implementation programmes are needed because it has been shown that the outcome of disease may be favourably influenced by the thorough application of clinical recommendations. Thus, the task of writing Guidelines or Expert Consensus Docu- ments covers not only the integration of the most recent research, but also the creation of educational tools and implementation programmes for the recommendations. The loop between clinical research, the writing of guidelines, and implementing them into clinical practice can then only be completed if surveys and regis- tries are performed to verify that real-life daily practice is in keeping with what is recommended in the guidelines. Such surveys and registries also make it possible to evaluate the impact of implementation of the guidelines on patient outcomes. Guidelines and recommendations should help physicians to make decisions in their daily practice; however, the ultimate judgement regarding the care of an individual patient must be made by the physician in charge of that patient’s care. Introduction Pulmonary embolism (PE) is a relatively common cardiovascular emergency. By occluding the pulmonary arterial bed it may lead to acute life-threatening but potentially reversible right ventricular failure. PE is a difficult diagnosis that may be missed because of non-specific clinical presentation. However, early diagnosis is fun- damental, since immediate treatment is highly effective. Depending on the clinical presentation, initial therapy is primarily aimed either at life-saving restoration of flow through occluded pulmonary arteries (PA) or at the prevention of potentially fatal early recur- rences. Both initial treatment and the long-term anticoagulation that is required for secondary prevention must be justified in each patient by the results of an appropriately validated diagnostic strategy.1 Epidemiology, predisposing factors, natural history, and the pathophysiology of PE have been described more extensively else- where.2–5 This document focuses on currently available and vali- dated methods of diagnosis, prognostic evaluation and therapy of PE. In contrast to previous guidelines, we decided to grade also the level of evidence of diagnostic procedures. The most robust data come from large-scale accuracy or outcome studies. Accuracy studies are designed to establish the characteristics of a diagnostic test (sensitivity and specificity) by comparing test results with a reference diagnostic criterion (the so-called gold standard). Outcome studies evaluate patient outcomes when a given diagnostic test or strategy is used for clinical decision-making. In the field of PE, the outcome measurement is the rate of thromboembolic events [deep vein thrombosis (DVT) or PE] during a 3-month follow-up period in patients left untreated by anticoagulants. The reference for comparison is the rate of DVT or PE in patients left untreated after a negative conventional . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Table 1 Classes of recommendations Class I Evidence and/or general agreement that a given treatment or procedure is beneficial, useful, and effective Class II Conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of the given treatment or procedure Class IIa Weight of evidence/opinion is in favour of usefulness/efficacy Class IIb Usefulness/efficacy is less well established by evidence/opinion Class III Evidence or general agreement that the given treatment or procedure is not useful/ effective, and in some cases may be harmful Table 2 Levels of evidence Level of evidence A Data derived from multiple randomized clinical trialsa or meta-analyses Level of evidence B Data derived from a single randomized clinical triala or large non-randomized studies Level of evidence C Consensus of opinion of the experts and/or small studies, retrospective studies, registries aOr large accuracy or outcome trial(s) in the case of diagnostic tests or strategies. ESC Guidelines2278 pulmonary angiogram, which is around 1–2%, with an upper limit of the 95% confidence interval (CI) of 3% during a 3-month follow-up.6 The advantage of outcome studies is that they are easily carried out under normal clinical circumstances and their results are therefore generalizable. However, they do not yield any information on false positives and potential overtreatment. We used the following criteria for grading levels of evidence from diagnostic studies: † Data derived from multiple comparisons or outcome studies or meta-analyses are considered level of evidence A. † Data from a single large comparison or outcome study are con- sidered level of evidence B. † Expert consensus and/or data derived from small comparison or outcome studies are considered level of evidence C. The first edition of the ESC Clinical Practice Guidelines on PE, published in 2000, was among the documents most often down- loaded from the Eur Heart J Web Site.7 We dedicate the current Guidelines to Prof. Henri Denolin, former President of the ESC, Prof. Mireille Brochier, former President of the French Cardiac Society, Prof. Jiri Widimsky, former President of the Cze- choslovak Cardiac Society, and Prof. Mario Morpurgo, former Chairman of the ESC Working Group on Pulmonary Circulation, and to other eminent cardiologists who paved the path towards the more effective diagnosis and clinical management of acute pul- monary embolism. Epidemiology PE and DVT are two clinical presentations of venous thromboem- bolism (VTE) and share the same predisposing factors. In most cases PE is a consequence of DVT. Among patients with proximal DVT, about 50% have an associated, usually clinically asymptomatic PE at lung scan.8 In about 70% of patients with PE, DVT can be found in the lower limbs if sensitive diagnostic methods are used.5,9 The epidemiology of VTE has recently been reviewed.4 Although DVT and PE are manifestations of a single disease, namely VTE, PE has features that are distinct from DVT. The risk of death related to the initial acute episode or to recurrent PE is greater in patients who present with PE than in those who present with DVT.10 According to prospective cohort studies, the acute case fatality rate for PE ranges from 7 to 11%.11 Also, recurrent episodes are about three times more likely to be PE after an initial PE than after an initial DVT (about 60% after PE vs. 20% after DVT).11 The prevalence of PE among hospitalized patients in the United States, according to data collected between 1979 and 1999, was 0.4%.12 Though only 40–53 per 100 000 persons were diagnosed with PE per year, the annual incidence in the United States was estimated at 600 000 cases.13 The corresponding figures for Europe are unavailable. Among regional registries, an analysis of 2356 autopsies performed in 1987 on 79% of all deceased inhabi- tants from the city of Malmo, Sweden, with a population of 230 000, revealed VTE in 595 (25%), while PE was found in 431 (18.3%) of all cases.14 In 308 autopsies (13.1%), PE was considered to be the main cause or a contributory cause of death. The inci- dence of PE, as diagnosed by lung scintigraphy, within the same period and population was only 48 (2%) cases in the whole Malmo region. From autopsy, phlebography and lung scintigraphy results, the authors estimated the incidence of VTE in the city of Malmo at 42.5/10 000 inhabitants/year. However, recalculation of their data indicates that the incidence of PE was 20.8/10 000 inhabitants/year.14 In a more recent community-based study involving 342 000 inhabitants in Brittany, France, the incidences of VTE and PE were 18.3 and 6.0/10 000/year respectively. However, autopsy data were not available.15 The true incidence of PE is therefore difficult to assess in view of its non-specific clinical presentation.16 Predisposing factors Although PE can occur in patients without any identifiable predis- posing factors, one or more of these factors are usually identified (secondary PE). The proportion of patients with idiopathic or unprovoked PE was about 20% in the International Cooperative Pulmonar